FPF
NVLN

FNY Partners Fund’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

FNY Partners Fund’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,917
Closed -$54K – 770
2017
Q2 		$54K Buy
5,917
+4,817
+438% +$46.4K 0.01% 264
2017
Q1 		$11K Buy
+1,100
New +$11.2K ﹤0.01% 1083

Other funds holding NVLN

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EdgePoint Investment Group
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
Highbridge Capital Management
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FNY Partners Fund's NVLN Position: Q3 2017 in Review

FNY Partners Fund sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q3 2017, closing a stake of 5,917 shares — an estimated $54K sold.

FNY Partners Fund first reported a position in NVLN in Q1 2017 and held it in 2 quarters. The position peaked at $54K in Q2 2017. 72 funds tracked by Wall St. Rank hold NVLN as of Q3 2017.

  • FNY Partners Fund reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q3 2017 after selling out during the quarter.
  • FNY Partners Fund sold 5,917 Novelion Therapeutics Inc. Common Shares shares in Q3 2017, an estimated $54K.
  • FNY Partners Fund first reported a position in Novelion Therapeutics Inc. Common Shares in Q1 2017 and held it in 2 quarters.
  • FNY Partners Fund's Novelion Therapeutics Inc. Common Shares position peaked at $54K in Q2 2017.
  • 72 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q3 2017.

Based on FNY Partners Fund's 13F filing for Q3 2017, filed 9 Nov 2017.